LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients

Clinical Genetics

Volumn 52, Issue 5, 1997, Pages 377-386

  Kronenberg, Florian ^a,d   Trenkwalder, Evi ^a   Sturm, Wolfgang ^b   Kathrein, Hermann ^b   König, Paul ^b   Neyer, Ulrich ^c   Gröchenig, Ernst ^c   Utermann, Gerd ^a   Dieplinger, Hans ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c Landeskrankenhaus Feldkirch   (Austria)

^d Inst of Med Biol and Hum Genet   (Austria)

Author keywords

Apo(a) phenotype; Atherosclerosis; Carotid arteries; Carotid atherosclerosis; End stage renal disease; Free apo(a); LDL unbound apo(a); Lp(a)

Indexed keywords

APOLIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGINA PECTORIS; ATHEROSCLEROSIS; CAROTID ARTERY; CONFERENCE PAPER; FEMALE; HEMODIALYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ANGINA;

EID: 0031409226     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.1997.tb04357.x     Document Type: Conference Paper

References (60)

1. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991: 39: 169-183.
2. Auguet T, Sentí M, Rubies-Prat J, Pelegrí A, Pedro-Botet J, Nogués X, Romero R. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993: 8: 1099-1103.
3. Black IW, Wilcken DEL. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992: 38: 353-357.
4. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992: 90: 52-60.
5. Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 1994: 90: 1688-1695.
6. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994: 9: 1136-1142.
7. Budowle B, Giusti AM, Waye JS, Baechtel FS, Fourney RM, Adams DE, Presley LA, Deadman HA, Monson KL. Fixed-bin analysis for statistical evaluation of continuous distributions of allelic data from VNTR loci, for use in forensic comparisons. Am J Hum Genet 1991: 48: 841-855.
8. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein(a). J Clin Invest 1995: 96: 1639-1646.
9. Cantin B, Moorjani S, Després J-P, Dagenais GR, Lupien P-J. Lp(a) in ischemic heart disease. The Québec Cardiovascular Study. J Am Coll Cardiol 1994: 23: 482A (Abstract).
10. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994: 24: 444-453.
11. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992: 86: 475-482.
12. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Arterioscler Thromb 1989: 9: 593-603.
13. Demeester CA, Bu X, Gray RJ, Lusis AJ, Rotter JI. Genetic variation in lipoprotein (a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein(a) gene locus. Am J Hum Genet 1995: 56: 287-293.
14. Dieplinger H, Gruber G, Krasznai K, Reschauer S, Seidel C, Burns G, Müller H-J, Császár A, Vogel W, Robenek H, Utermann G. Kringle 4 of human apolipoprotein(a) shares a linear antigenic site with human catalase. J Lipid Res 1995: 36: 813-822.
15. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993: 91: 397-401.
16. Fiorini F, Masturzo P, Mij M, Bertolini S. Lipoprotein(a) levels in hemodialysis patients: relation to glucose intolerance and hemodialysis duration. Nephron 1995: 70: 500-501.
17. Gries A, Nimpf J, Nimpf M, Wurm H, Kostner GM. Free and Apo B-associated Lpa-specific protein in human serum. Clin Chim Acta 1987: 164: 93-100.
18. Held PJ, Port FK, Webb RL, Wolfe RA, Bloembergen WE, Turenne MN, Holzman E, Ojo AO, Young EW, Mauger EA, et al. Excerpts from United States Renal Data System 1995 Annual Data Report. Am J Kidney Dis 1995: 26: S1-S186.
19. Hirata K, Kikuchi S, Saku K, Jimi S, Zhang B, Naito S, Hamaguchi H, Arakawa K. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 1993: 44: 1062-1070.
20. Jamieson DG, Usher DC, Rader DJ, Lavi E. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels - a potential role for endothelial cells in lesion formation. Am J Pathol 1995: 147: 1567-1574.
21. Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 1991: 49: 1063-1074.
22. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F. ApoB, fibrinogen, HDL cholesterol and apo(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997: 8: 1889-1898.
23. Kraft HG, Dieplinger H, Hoye E, Utermann G. Lp(a) phenotyping by immunoblotting with polyclonal and monoclonal antibodies. Arteriosclerosis 1988: 8: 212-216.
24. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992: 90: 220-230.
25. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996a: 125: 53-61.
26. Kraft HG, Lingenhel A, Köchl S, Hoppichler F, Kronenberg F, Abe A, Mühlberger V, Schönitzer D, Utermann G. Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996b: 16: 713-719.
27. Kronenberg F, Dieplinger H, König P, Utermann G. Lipoprotein metabolism in renal replacement therapy: a review. Isr J Med Sci 1996a: 32: 371-389.
28. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994a: 14: 1405-1411.
29. Kronenberg F, König P, Lhotta K, Öfner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H. Apolipoprotein(a) phenotype associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994b: 14: 1399-1404.
30. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995: 6: 110-120.
31. Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res 1994c: 35: 1318-1328.
32. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 1996b: 33: 495-543.
33. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, Moes N, König P, Utermann G, Dieplinger H. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J Lipid Res 1997: 3: 1755-1763.
34. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996e: 27: 1-25.
35. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991: 87: 2153-2161.
36. London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997: 51: 1678-1695.
37. Mancini FP, Newland DL, Mooser V, Murata J, Marcovina S, Young SG, Hammer RE, Sanan DA, Hobbs HH. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 1995: 15: 1911-1916.
38. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995: 41: 246-255.
39. Mölgaard J, Klausen IC, Lassvik C, Fœrgeman O, Gerdes LU, Olsson AG. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 1992: 12: 895-901.
40. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996: 98: 2414-2424.
41. Parlavecchia M, Pancaldi A, Taramelli R, Valsania P, Galli L, Pozza G, Chierchia S, Ruotolo G. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men ≤55 years of age. Am J Cardiol 1994: 74: 346-351.
42. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987: 33: 721.
43. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991: 32: 317-327.
44. Rader DJ, Hoeg JM, Brewer HB, Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994: 120: 1012-1025.
45. Raine AEG, MacMahon SH, Selwood NH, Wing AJ, Brunner FP. Mortality from myocardial infarction in patients on renal replacement therapy in the UK. Nephrol Dial Transplant 1991: 6: 902 (Abstract)
46. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989: 9: 579-592.
47. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle-aged men. BMJ 1990: 301: 1248-1251.
48. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoiorms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992: 12: 1214-1226.
49. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994: 271: 999-1003.
50. Segarra A, Chacon P, Martin M, Vilardell M, Vila J, Cotrina M, Fort J, Olmos A, Piera LL. Serum lipoprotein (a) levels in patients with chronic renal failure: evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron 1995: 69: 9-13.
51. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992: 69: 1251-1254.
52. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993: 44: 1116-1123.
53. Trenkwalder E, Gruber A, König P, Dieplinger H, Kronenberg F. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997: 52: 1685-1692.
54. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987: 80: 458-465.
55. Wald NJ, Law M, Watt HC, Wu TS, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994: 343: 75-79.
56. Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 1995: 10: 75-81.
57. Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993: 119: 263-269.
58. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 1993: 341: 268-270.
59. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995: 10: 354-357.
60. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997: 17: 239-245.